Krebs Biochemicals Reports Mixed Financial Results Amidst Operational Challenges in June 2025

Krebs Biochemicals & Industries has recently reported its financial results for the quarter ending June 2025, revealing a complex picture of its performance. The company has experienced a notable adjustment in its evaluation, with its score shifting to -16 from -25 over the past three months.
On a positive note, Krebs Biochem has achieved its highest operating profit in the last five quarters, recording Rs -2.09 crore. This suggests a near-term positive trend in operating profit. Additionally, the company has demonstrated efficiency in managing its receivables, as evidenced by a significant increase in its Debtors Turnover Ratio, which reached 866.40 times over the last half-year periods.

Conversely, the financial results also highlight significant challenges. Net sales for the quarter stood at Rs 5.48 crore, reflecting a substantial decline of 57.49% year-on-year. Furthermore, the Profit After Tax for the latest six months was reported at Rs -13.59 crore, marking a decrease of 53.42% year-on-year. The company's debt-equity ratio has also reached its highest point at -1.45 times, indicating a reliance on borrowing to sustain operations, which may impact liquidity.

Overall, Krebs Biochemicals & Industries is navigating a challenging financial landscape, with both positive developments and significant hurdles to address.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.